Pfizer reports positive Phase II data for PF-07872412 in infants

Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, in infants. After the fourth dose, the titers were approximately 15-fold higher with 25vPnC than PREVNAR 20. The vaccine candidate is projected to cover 90% serotypes in children under five, with 15% attributed to serotype 3. Credit: Minerva Studio / Shutterstock.com. Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. The trial compared 25vPnC to PREVNAR 20 (PCV20) over a four-dose schedule at two, four, six, and 12-15 months of…

Source: Clinical Trials Arena